Fatih M. Uckun, LM Chelstrom, D Finnegan, L Tuel-Ahlgren, Carlos Manivel, JD Irvin, Damian E. Myers, Roland Günther,
... of 434 SCID mice, the antileukemic efficacy of B43 (anti-CD19)-pokeweed antiviral protein (PAP) immunotoxin and ... as individual reagents and as combined immunochemotherapeutic regimens. B43-PAP plus CPA was superior to either the ... 10(6) leukemia cells and then treated with B43-PAP plus CPA combined immunochemotherapy regimens became long-term survivors, a result not achieved with B43-PAP alone or CPA alone. The advantage was ... 10(6) leukemia cells. While neither 15 micrograms B43-PAP (median survival, 58 days) nor 1 mg ...
Tópico(s): Acute Lymphoblastic Leukemia research
1992 - Elsevier BV | Blood
Fatih M. Uckun, LM Chelstrom, D Finnegan, L Tuel-Ahlgren, Carlos Manivel, JD Irvin, Damian E. Myers, Roland Günther,
... of 434 SCID mice, the antileukemic efficacy of B43 (anti-CD19)-pokeweed antiviral protein (PAP) immunotoxin and ... as individual reagents and as combined immunochemotherapeutic regimens. B43-PAP plus CPA was superior to either the ... 10(6) leukemia cells and then treated with B43-PAP plus CPA combined immunochemotherapy regimens became long-term survivors, a result not achieved with B43-PAP alone or CPA alone. The advantage was ... 10(6) leukemia cells. While neither 15 micrograms B43-PAP (median survival, 58 days) nor 1 mg ...
Tópico(s): Acute Lymphoblastic Leukemia research
1992 - Elsevier BV | Blood
Rauf Onur Ek, Paul S. Gaynon, Tamer Zeren, Lisa M. Chelstrom, Dorothea E. Myers, Fatih M. Uckun,
... the antileukemic activity of the investigational biotherapeutic agent B43-PAP to the antileukemic activities of the standard ... event-free survival (EFS) of 47 ± 6 days. B43-PAP was more active than VCR, PDN, or L-ASP and the two-drug combinations VCR+B43-PAP, PDN+B43-PAP, or L-ASP + B43-PAP were not significantly more active than B43-PAP. The 120 days EFS outcome results were 46 ± 13% for B43-PAP (Median EFS = 92 ± 22 days), 0 ± 0% ... EFS = 41 ± 1 days), 60 ± 22% for VCR + B43-PAP (Median EFS = >120 days), 60 ± 22% for PDN + B43-PAP (Median EFS = >120 days), and 50 ± 25% ...
Tópico(s): Acute Lymphoblastic Leukemia research
1998 - Taylor & Francis | Leukemia & lymphoma/Leukemia and lymphoma
Fatih M. Uckun, Carlos Manivel, DC Arthur, LM Chelstrom, D Finnegan, L Tuel-Ahlgren, JD Irvin, Damian E. Myers, Robert Günther,
... to evaluate the in vivo antileukemic efficacy of B43 (anti-CD19)-pokeweed antiviral protein (PAP) immunotoxin. A 3-day treatment with nontoxic doses of B43- PAP markedly reduced the incidence of paraplegia and ... 18% +/- 8% for mice treated with 15 micrograms B43-PAP (5 micrograms/mouse/d x 3 days) ( ... 5% +/- 5% for mice treated with 30 micrograms B43-PAP (10 micrograms/mouse/d x 3 days) ( ... 24 to 54 days), only 16 of 44 B43-PAP-treated mice developed leukemia at 74 +/- 12 ... 65% +/- 10% for mice treated with 15 micrograms B43-PAP and 60% +/- 11% for mice treated with ...
Tópico(s): Veterinary medicine and infectious diseases
1992 - Elsevier BV | Blood
Dorothea E. Myers, J D Irvin, Ron S. Smith, V Kuebelbeck, Fatih M. Uckun,
... homogeneity by successive steps of ion exchange chromatography. B43 MoAb was produced in vitro by hollow fiber ... to homogeneity by affinity chromatography. PAP toxin and B43 MoAb were modified via their free amino groups ... used to introduce 2-pyridyl disulfide bonds into B43 MoAb. Modified PAP was reacted with modified B43 MoAb resulting in a sulfhydryl-disulfide exchange reaction and yielding disulfide linked PAP-B43 MoAb conjugates, which we refer to as B43-PAP immunotoxin. B43-PAP immunotoxin was subjected to ...
Tópico(s): Plant tissue culture and regeneration
1991 - Elsevier BV | Journal of Immunological Methods
Richard P. Baum, A.A. Noujaim, Andreea A. Nanci, Volker Moebus, A. Hertel, A. Niesen, B. Donnerstag, T.R. Sykes, G. R. Boniface, G. Hör,
... Repeated Stimulation of HAMA Using MAb OC125 and B43.13R.P. BAUM, A.A. NOUJAIM, A. NANCI, ... 15, No. 6Immune responses to murine monoclonal antibody-B43.13 correlate with prolonged survival of women with ... T Cell Responses in Patients Injected with MAb-B43.13—Evidence for Antibody-Mediated Antigen-Processing and ... 1Immunotherapy of Human Ovarian Carcinoma with OVAREXTM MAb-B43.13 in a Human-PBL-SCID/BG Mouse ... to the Murine Monoclonal Anti-CA 125 Antibody B43.1316 April 2018 | The International Journal of Biological ...
Tópico(s): CAR-T cell therapy research
1993 - Mary Ann Liebert, Inc. | Hybridoma
Roland Günther, Lisa M. Chelstrom, Heather Wendorf, Elizabeth Schneider, Kristi Covalciuc, Bradley K. Johnson, Dina Clementson, J D Irvin, Dorothea E. Myers, Fatih M. Uckun,
The investigational biotherapeutic agent, B43(anti-CD19)-pokeweed antiviral protein (PAP) immunotoxin, has shown substantial anti-leukemic activity in SCID mouse models of human B- ... toxicity study which determined the toxicity profile of B43-PAP in BALB/c mice. Administration of un-conjugated B43 monoclonal antibody was not associated with any toxicity, whereas B43-PAP caused dose-limiting and cardiac and renal toxicities which were fatal. In addition, B43-PAP also caused multifocal skeletal myofiber necrosis, which ...
Tópico(s): Acute Lymphoblastic Leukemia research
1996 - Taylor & Francis | Leukemia & lymphoma/Leukemia and lymphoma
A.A. Noujaim, Birgit C. Schultes, Richard P. Baum, Ragupathy Madiyalakan,
The murine monoclonal anti-CA125 antibody MAb-B43.13 has previously been administered as an immunoscintigraphic agent in order to monitor recurrence of ovarian cancer in patients, and a long-term ... was to investigate the role of CA125-MAb-B43.13 immune complex formation on the induction of ... antibody injection. Subsequent to the injection of MAb-B43.13, the patients generated anti-CA125 antibodies that ... restricted to the specific epitope recognized by MAb-B43.13. The generation of CA125-specific B and ...
Tópico(s): Ovarian cancer diagnosis and treatment
2001 - Mary Ann Liebert, Inc. | Cancer Biotherapy and Radiopharmaceuticals
Holly J. Meany, Nita L. Seibel, Mark Krailo, Doojduen Villaluna, Zhengjia Chen, Paul S. Gaynon, Joseph P. Neglia, Julie R. Park, Raymond J. Hutchinson, Judith K. Sato, Robert J. Wells, William G. Woods, Gregory Reaman,
Background: B43-pokeweed antiviral protein (B43-PAP) is a high-affinity anti-CD19 immunotoxin that is capable of causing apoptotic death in B-lineage leukemic cells with a drug-resistant phenotype. B43-PAP exhibited in vivo antileukemic activity in preclinical ... study evaluated the toxicity profile and efficacy of B43-PAP immunotoxin in combination with standard induction chemotherapy ... leukemia (B-ALL). Pharmacokinetic profile and immunogenicity of B43-PAP were assessed. Experimental Design: B43-PAP in ...
Tópico(s): Neuroblastoma Research and Treatments
2015 - Lippincott Williams & Wilkins | Journal of Immunotherapy
Fatih M. Uckun, K Gajl-Peczalska, John H. Kersey, L. L. Houston, Daniel A. Vallera,
... 3 (anti-CD10), BA-1 (anti-CD24), and B43 mAb have allowed us to define two distinct ... group had BA-2+, BA-3+, BA-1+, B43+ marker profiles, consistent with the phenotype of uncultured ... A pan-B immunotoxin was synthesized by linking B43, a human B cell-specific mAb, to pokeweed antiviral protein (PAP). This study showed that B43-PAP can effectively eradicate leukemic progenitor cells freshly obtained from patients with common B-lineage ALL. B43-PAP eliminated greater than 99.96% of blast ... results establish that the surface determinant recognized by B43 is expressed on B-lineage progenitor cells in ...
Tópico(s): Acute Lymphoblastic Leukemia research
1986 - Rockefeller University Press | The Journal of Experimental Medicine
Rauf Onur Ek, Yuri Yanishevskic, Tamer Zeren, Barbara Waurzyniak, Roland Günther, Lisa M. Chelstrom, M Chandan-Langlie, Elizabeth Schneider, Dorothea E. Myers, William E. Evans, Fatih M. Uckun,
B43(anti-CD19)-Genistein immunoconjugate targets genistein, a naturally occurring protein tyrosine kinase inhibitory isoflavone to the ... In this preclinical study, the toxicity profiles of B43-Genistein as well as unconjugated genistein were evaluated in mice. B43-Genistein and genistein were administered either as single ... in any of the 64 genistein-treated mice. B43-Genistein had a significantly longer elimination half-life ... slower plasma and tissue clearance than unconjugated genistein. B43-Genistein was not toxic to mice at the ...
Tópico(s): Digestive system and related health
1998 - Taylor & Francis | Leukemia & lymphoma/Leukemia and lymphoma
Fatih M. Uckun, W Jaszcz, JL Ambrus, AS Fauci, K Gajl-Peczalska, CW Song, MR Wick, Damian E. Myers, KG Waddick, JA Ledbetter,
... marker analyses and binding competition assays demonstrated that B43 monoclonal antibody (MoAb) is a new member of ... as several other anti-CD19 MoAbs. We used B43 MoAb to test for CD19 expression on neoplastic ... marrow progenitor cells; (b) ligation of CD19 with B43 MoAb induces sustained increases in [Ca2+]i when ... under coordinate regulatory control; (d) approximately two million B43 MoAb molecules per cell can be bound to ... 10(8)/mol/L; (e) CD19 can undergo B43 MoAb-induced internalization; and (f) the opportunity is ...
Tópico(s): T-cell and B-cell Immunology
1988 - Elsevier BV | Blood
Fatih M. Uckun, W Jaszcz, JL Ambrus, AS Fauci, K Gajl-Peczalska, CW Song, MR Wick, Damian E. Myers, KG Waddick, JA Ledbetter,
... marker analyses and binding competition assays demonstrated that B43 monoclonal antibody (MoAb) is a new member of ... as several other anti-CD19 MoAbs. We used B43 MoAb to test for CD19 expression on neoplastic ... marrow progenitor cells; (b) ligation of CD19 with B43 MoAb induces sustained increases in [Ca2+]i when ... under coordinate regulatory control; (d) approximately two million B43 MoAb molecules per cell can be bound to ... 10(8)/mol/L; (e) CD19 can undergo B43 MoAb-induced internalization; and (f) the opportunity is ...
Tópico(s): Immunotherapy and Immune Responses
1988 - Elsevier BV | Blood
Fatih M. Uckun, LM Chelstrom, JD Irvin, D Finnegan, Robert Günther, Jo‐Anne H. Young, V Kuebelbeck, Damian E. Myers, L. L. Houston,
... with the anti-human CD19 monoclonal antibodies (MoAb) B43, B4, Leu-12, and J3–119. In contrast ... the human CD19 cDNA probe, (2) react with B43/anti-CD19 MoAb, or (3) express the 69- ... vivo homing ability, pharmacokinetics, and antileukemic efficacy of B43 MoAb conjugated to the plant hemitoxin pokeweed antiviral protein (PAP). B43-PAP immunotoxin (1) showed strong and antigen-specific ... mice and, most importantly, (4) improved survival. Finally, B43-PAP immunotoxin was more effective against BCL-1 ...
Tópico(s): Acute Lymphoblastic Leukemia research
1992 - Elsevier BV | Blood
Fatih M. Uckun, LM Chelstrom, JD Irvin, D Finnegan, Roland Günther, Jo‐Anne H. Young, V Kuebelbeck, Damian E. Myers, L. L. Houston,
... with the anti-human CD19 monoclonal antibodies (MoAb) B43, B4, Leu-12, and J3–119. In contrast ... the human CD19 cDNA probe, (2) react with B43/anti-CD19 MoAb, or (3) express the 69- ... vivo homing ability, pharmacokinetics, and antileukemic efficacy of B43 MoAb conjugated to the plant hemitoxin pokeweed antiviral protein (PAP). B43-PAP immunotoxin (1) showed strong and antigen-specific ... mice and, most importantly, (4) improved survival. Finally, B43-PAP immunotoxin was more effective against BCL-1 ...
Tópico(s): Plant tissue culture and regeneration
1992 - Elsevier BV | Blood
Volker Möbus, Richard P. Baum, Marcus Bolle, R. Kreienberg, A.A. Noujaim, Birgit C. Schultes, Christopher F. Nicodemus,
... the therapeutic efficiency of the murine monoclonal antibody-B43.13 in the treatment of patients with recurrent ... were treated with technetium 99m-labeled monoclonal antibody-B43.13, a murine monoclonal antibody that is directed ... human anti-murine antibodies against the monoclonal antibody-B43.13 variable region (Ab(2)) and antibodies that ... months after the first dose of monoclonal antibody B43.13; 34.1% of the patients survived >24 ... and improved clinical outcomes suggest that monoclonal antibody-B43.13 should be further evaluated for potential use ...
Tópico(s): Toxin Mechanisms and Immunotoxins
2003 - Elsevier BV | American Journal of Obstetrics and Gynecology
KG Waddick, Damian E. Myers, Roland Günther, LM Chelstrom, M Chandan-Langlie, JD Irvin, Nilgun E. Tumer, Fatih M. Uckun,
... study, we examined the antileukemic efficacy of the B43 (anti-CD19)-pokeweed antiviral protein (B43-PAP) immunotoxin against radiation-resistant BCP leukemia cells. B43-PAP caused apoptosis of radiation-resistant primary BCP ... resistant human BCP leukemia. Furthermore, the combination of B43-PAP and total body irradiation (TBI) was more ... models of radiation- resistant human BCP leukemia. Thus, B43-PAP may prove useful in the treatment of ...
Tópico(s): CAR-T cell therapy research
1995 - Elsevier BV | Blood
Dorothea E. Myers, Andrew R. Sicheneder, Dina Clementson, Nancy Dvorak, T.K. Venkatachalam, Alexander Rostov Sev, M Chandan-Langlie, Fatih M. Uckun,
... conjugated the murine monoclonal anti-CD 19 antibody B43 to the tyrosine kinase inhibitor genistein to construct ... malignancies. The scaled-up production and purification of B43 antibody, genistein, and B43-Genistein immunoconjugate permitted the manufacturing of a highly purified clinical-grade B43-Genistein preparation. In clonogenic assays, B43-Genistein elicited selective and potent cytotoxicity against CD ...
Tópico(s): Transgenic Plants and Applications
1998 - Taylor & Francis | Leukemia & lymphoma/Leukemia and lymphoma
Birgit C. Schultes, Theresa L. Whiteside,
The CA125 (carcinoma antigen 125)-specific antibody MAb-B43.13 (OvaRex MAb-B43.13) is in clinical trials for patients with ... complexes (IC) of CA125 and monoclonal antibody (MAb)-B43.13 or CA125 antigen alone. Proliferation assays were ... U/ml and 5 microg/ml of MAb-B43.13. The data indicate that precursor cells specific ... in ovarian cancer patients after immunization with MAb-B43.13.
Tópico(s): T-cell and B-cell Immunology
2003 - Elsevier BV | Journal of Immunological Methods
Sai Kiran Sharma, Kuntal K. Sevak, Sébastien Monette, Sean Carlin, James C. Knight, Frank Wuest, Evis Sala, Brian M. Zeglis, Jason S. Lewis,
... recurrence and metastases. Methods: 89 Zr-labeled mAb-B43.13 was synthesized to target CA125 and evaluated ... Results: PET imaging using 89 Zr-DFO-mAb-B43.13 (DFO is desferrioxamine) clearly delineated CA125-positive ... studies revealed accretion of 89 Zr-DFO-mAb-B43.13 in the OVCAR3 tumors, ultimately reaching 22. ... low-activity concentrations of 89 Zr-DFO-mAb-B43.13 accumulated in CA125-negative SKOV3 tumors. Conclusion: Immuno-PET with 89 Zr-labeled mAb-B43.13 is a potential strategy for the noninvasive ...
Tópico(s): Ovarian cancer diagnosis and treatment
2016 - Society of Nuclear Medicine and Molecular Imaging | Journal of Nuclear Medicine
S.A. McQuarrie, R. P. Baum, A. Niesen, Ragupathy Madiyalakan, W. KORZ, T.R. Sykes, C Sykes, G. Hör, Alexander McEwan, A.A. Noujaim,
OVAREX MAb B43.13 is a new radiopharmaceutical based on a monoclonal antibody (MAb-B43.13) known to recognize CA 125, a tumour ... The serum and renal clearances for 99Tcm-MAb-B43.13 were 121 and 53 ml h-1 ... Based on the serum pharmacokinetics of 99Tcm-MAb-B43.13 and whole-body planar gamma camera images, ...
Tópico(s): Radiation Therapy and Dosimetry
1997 - Lippincott Williams & Wilkins | Nuclear Medicine Communications
Birgit C. Schultes, Chengsheng Zhang, Liyan Xue, A.A. Noujaim, Ragupathy Madiyalakan,
The monoclonal antibody (MAb) B43.13, binding to the ovarian cancer-associated antigen CA125, has been injected into more than 200 patients with ovarian cancer ... To investigate the therapeutic effectiveness of OvaRexTM MAb-B43.13 (AltaRex, Edmonton, Canada) under well-controlled conditions, ... to 3 x 107 PBL/mouse. OvaRexTM MAb-B43.13 was administered at 100 μg/mouse in ... mice. All three experiments showed that OvaRexTM MAb-B43.13 treatment could (a) delay or prevent development ...
Tópico(s): Toxin Mechanisms and Immunotoxins
1999 - Mary Ann Liebert, Inc. | Hybridoma
MF Van Bressem, Koen Van Waerebeek, Aquiles García-Godos, D. Dekegel, P.-P. Pastoret,
... Immunology, Faculty of Veterinary Medicine, University of Liége, B43, Local R80, Sart Tilman, 4000 Liége, Belgium.Search ... Immunology, Faculty of Veterinary Medicine, University of Liége, B43, Local R80, Sart Tilman, 4000 Liége, Belgium. Centro ... Immunology, Faculty of Veterinary Medicine, University of Liége, B43, Local R80, Sart Tilman, 4000 Liége, Belgium.Search ... Immunology, Faculty of Veterinary Medicine, University of Liége, B43, Local R80, Sart Tilman, 4000 Liége, Belgium. Centro ...
Tópico(s): Animal Virus Infections Studies
1994 - Wiley | Marine Mammal Science
Fatih M. Uckun, Dorothea E. Myers, James D. Irvin, V Kuebelbeck, D Finnegan, Lisa M. Chelstrom, L. L. Houston,
... SMPT, to generate an intermolecular bridge between the B43 MoAb and PAP toxin moieties. These immunotoxins were ... c) in vivo anti-leukemic activity of various B43-PAP immunotoxin constructs. Our data recommend the use ... SMPT rather than LC-SPDP for generation of B43(anti-CD19)-PAP immunotoxins as clinical anti-leukemic ...
Tópico(s): Transgenic Plants and Applications
1993 - Taylor & Francis | Leukemia & lymphoma/Leukemia and lymphoma
Dorothea E. Myers, Yuri Yanishevski, Eric Masson, James D. Irvin, William E. Evans, Fatih M. Uckun,
... report, we describe the preparation and characterization of B43(anti-CD19)-pokeweed antiviral protein (PAP) immunotoxins containing ... toxin molecules covalently linked to each 150 kDa B43 monoclonal antibody molecule. Compared to the 180 kDa ... study recommend the clinical evaluation of 210 kDa B43-PAP as a potentially more effective immunotoxin against ...
Tópico(s): Plant tissue culture and regeneration
1995 - Taylor & Francis | Leukemia & lymphoma/Leukemia and lymphoma
T.R. Sykes, Vijayalakshmi V. Somayaji, Stefan Bier, Thomas K. Woo, Cheuk S. Kwok, Victor Snieckus, A.A. Noujaim,
... novel method for direct radiolabeling of monoclonal antibody B43.13 (MAb-B43.13) with 188Re and have evaluated the product' ... biochemical, immunochemical and selected biological properties. 188ReMAbB43.13 was readily prepared by the addition of ...
Tópico(s): Monoclonal and Polyclonal Antibodies Research
1997 - Elsevier BV | Applied Radiation and Isotopes
Thierry Jauniaux, G. Charlier, M. Desmecht, F. Coignoul,
... Department of Pathology, Veterinary College, Sart Tilman Bat B43, University of Liege, 4000 Liege, BelgiumSearch for more ... Department of Pathology, Veterinary College, Sart Tilman Bat B43, University of Liege, 4000 Liege, BelgiumSearch for more ... Department of Pathology, Veterinary College, Sart Tilman Bat B43, University of Liege, 4000 Liege, BelgiumSearch for more ... Department of Pathology, Veterinary College, Sart Tilman Bat B43, University of Liege, 4000 Liege, BelgiumSearch for more ...
Tópico(s): Respiratory viral infections research
1998 - Wiley | Veterinary Record
Rauf Onur Ek, Gregory H. Reaman, Daune L. Crankshaw, Lisa M. Chelstrom, Dorothea E. Myers, Fatih M. Uckun,
... repair by blocking the obligatory thymidine nucleotide synthesis. B43(anti-CD19)-PAP immunotoxin is a potent inhibitor ... 2 days (P < 0.001, log-rank test). B43-PAP treatment was more effective than ZD1694 (P= ... log-rank test). The combination of ZD1694 and B43-PAP was more effective than either agent alone ...
Tópico(s): Acute Lymphoblastic Leukemia research
1998 - Taylor & Francis | Leukemia & lymphoma/Leukemia and lymphoma
Chun‐Lin Chen, Alexandra M. Levine, Asha Rao, Karen O’Neill, Yoav H. Messinger, Dorothea E. Myers, Frederick D. Goldman, C. Hurvitz, James T. Casper, Fatih M. Uckun,
... the CD 19 receptor‐directed tyrosine kinase inhibitor B43‐Genistein in 17 patients (4 children, 13 adults) ... 7 hours , p = 0.04). The pharmacokinetics of B43‐Genistein was not affected by the gender of ... bone marrow transplantation in past medical history. Overall, B43‐Genistein showed favorable pharmacokinetics in this heavily pretreated ...
Tópico(s): Childhood Cancer Survivors' Quality of Life
1999 - Wiley | The Journal of Clinical Pharmacology
... B20D20+B40040+B43043+(B43043)*+AS·I]. Values for B43(B43=0, B43I=17 G) reported here, have not ... reported previously. By examining the temperature dependence of B43 and B40 a value for the fractional change ...
Tópico(s): Crystal Structures and Properties
1972 - American Institute of Physics | The Journal of Chemical Physics